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(33 MIs; 33 CABG/PTCAs; 11 strokes) with a total cost saving of
£332,512 (MI = £105,237; CABG/PTCA = £195,551; stroke =
£31,724). CONCLUSIONS: The estimated beneﬁt of treating to
an LDL-C target of <2.0 mmol/L rather than <3.0 mmol/L was
an additional 26 CV events avoided per 1000 patients with an
associated cost saving of £111,799.
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OBJECTIVES: A representative evaluation of CAD costs in
Poland including General Practitioners (GPs) and Specialists’ (S)
settings. METHODS: A representative sample of 2593 Polish
patients with conﬁrmed CAD (1977 patients under GP’s care,
616 patients under S care). A time horizon of the analysis was
12 month and a retrospective approach was applied. The study
estimated both direct medical and indirect costs resulted from
sick leaves, pensions and sickness beneﬁts. Unit costs were
obtained from available published data derived from the
National Health Fund and the Polish Social Insurance Institu-
tion. A prevalence based method using National Statistical
Ofﬁce data was used to estimate economic burden of CAD.
RESULTS: The distribution of total costs was similar in the
GPs’ and specialists’ settings. Hospitalisation and invasive treat-
ment constituted main direct medical costs’ drivers in both
conditions. The average direct medical cost per CAD patient
reached annually €1079.09. The average societal cost €1437.19
when the merely indirect costs related to the absence from
work (€358.10) was included. Average cost covering also indi-
rect cost related to the patients’ disability increased to the
€2254.17. The total average costs were signiﬁcantly (14.4%)
higher in Ss’ than in GPs’ settings. In accordance with the
lowest boundary estimate of CAD prevalence rate (2.9%), the
total, societal burden of CAD in Poland in 2005 amounted to
€2056.7 million. More than half of this cost (52.1%) was due
to the indirect cost, 69.5% of which resulted from patients’
disability. CONCLUSIONS: CAD imposes a high economic
burden for the third party payer as well as for Polish society.
Clearly, there is a need to develop and apply innovative, cost-
effective treatment strategies that will reduce the need for
hospitalisation and invasive treatment and may successfully be
implemented in the GPs’ practice.
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OBJECTIVES: We estimated incremental inpatient costs and
length of stay (LOS) attributable to secondary atrial ﬁbrillation
(AF) in patients with and without cardiac predisposing factors to
document the economic burden of this disease. METHODS: We
extracted 2004–2005 discharges from Premier Perspective(tm),
the largest hospital database in the US, with a secondary AF
diagnosis and matched controls that had neither a primary nor a
secondary AF diagnosis. We matched on patient age, discharge
date, facility type and primary diagnosis category. We used
regression models to estimate the incremental inpatient costs and
LOS due to secondary AF. We adjusted for comorbidities, demo-
graphic and hospital-speciﬁc factors. We repeated this analysis
for patients without cardiac predisposing factors (i.e. mitral valve
disease, heart failure, non-AF cardiac operation, chest pain and
congestive artery disease). RESULTS: The estimated 5.4 million
secondary AF discharges in the US during 2004 and 2005 had an
adjusted average inpatient cost of $12,292. This cost was $3532
more than the adjusted average inpatient cost for controls
without AF (P < 0.0001). Patients with secondary AF had an
adjusted average LOS of 7.8 days or 1.9 additional days com-
pared to controls without AF (P < 0.0001). The estimated 1.4
million secondary AF discharges without cardiac predisposing
factors had an adjusted average inpatient cost of $8956, an
increase of $1908 compared to controls without AF or cardiac
predisposing factors (P < 0.0001). Secondary AF patients
without cardiac predisposing factors had an adjusted average
LOS of 6.2 days or one additional day compared to controls
(P < 0.0001). CONCLUSIONS: Inpatient costs and LOS were
signiﬁcantly higher for patients with a secondary AF discharge
diagnosis when compared to controls that did not have an AF
diagnosis. These differences, although still signiﬁcant, were less
pronounced among patients without cardiac predisposing
factors. Further research is warranted to investigate how second-
ary AF is most cost-effectively treated.
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OBJECTIVES: Atherothrombosis is the leading cause of death
worldwide with huge economic burden. Peripheral arterial
disease (PAD), a marker of disseminated vascular disease, puts
patients at a high risk of atherothrombotic events. The REACH
Registry is an international prospective registry of 67,888
patients from 44 countries at risk of atherothrombosis due to
coronary artery disease (CAD), cerebrovascular disease (CVD)
and/or PAD, or the presence of3 atherothrombotic risk factors.
PAD at enrollment was identiﬁed on the basis of current inter-
mittent claudication with either ankle brachial index (ABI) < 0.9,
or history of lower limb revascularization (angioplasty/stenting,
peripheral bypass graft) or amputation. METHODS: We
examined 2-year rates of vascular-related hospitalizations and
associated costs in 1303 REACH patients from Germany with
established PAD at baseline. Poisson regression was used to
identify independent predictors of vascular hospitalizations. The
costs per DRG for vascular hospitalizations were derived from
the German 2004 Case Fees Catalogue. RESULTS: At baseline,
mean age was 68 years, 29% female, 46% diabetes, 76% had
ABI < 0.9, 56% had prior lower limb revascularization, 13%
prior amputation, 63% had other involved vascular territories
(479 CAD + PAD; 136 CVD + PAD; 205 CAD + CVD + PAD).
There were 360 (28%) patients who had 1 vascular hospital-
izations at 2 years. Signiﬁcant (p < 0.05) independent baseline
predictors of an increased hospitalization rate included diabetes,
female, ABI < 0.9, prior peripheral revascularization, prior
amputation, CAD, hypertension, decreasing age and prior
smoking. Mean vascular hospitalization costs per patient were:
€2595 overall; €3052 female/€2423 male; €3351/€1973 with/
without diabetes; €2773/€2394 with/without prior lower limb
revascularization; €2787/€2578 with/without prior amputation.
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